INTRODUCTION
Neural circuits control multiple organ systems to fine-tune function and maintain homeostasis, which is crucial for survival of multicellular organisms. During infection or tissue injury, detection of the presence of pathogens or damaged host cells activates the immune system to initiate inflammatory responses. This step is essential for combating invading pathogens and promoting tissue repair. Failure to resolve inflammation, however, contributes to tissue damage and organ dysfunction. Nonresolving inflammation underlies the pathogenesis of acute and chronic diseases, including rheumatoid arthritis, atherosclerosis, cancer, obesity and insulin resistance (1) . Previously, we identified a neural circuit, termed the "inflammatory reflex," which regulates the function of the innate immune system (2, 3) . This prototypical regulatory pathway requires the vagus nerve, splenic CD4 + T cells that relay neural signals and produce acetylcholine, and α7 nAchR expressed in splenic macrophages and other cytokineproducing immune cells (4) . Stimulation of the vagus nerve increases acetylcholine levels in the spleen, prevents excessive proinflammatory cytokine production during endotoxemia and experimental sepsis (4) , and reduces disease severity in human rheumatoid arthritis (5) . A key unsolved question is the molecular mechanism by which cholinergic neural signals regulate inflammatory responses in immune cells. Extracellular high-mobility group box 1 (HMGB1) released by activated immune cells or damaged tissue cells is a cytokine-like mediator of inflammation during sterile and infectious injury (6 (6) (7) (8) (9) . The molecular mechanism of HMGB1 release by activated immune cells depends on activation of inflammasomes. These are multiprotein complexes that cleave procaspase-1 to mediate the proteolytic maturation of interleukin (IL)-1β and IL-18, and pyroptosis, a form of proinflammatory programmed cell death (10) (11) (12) (13) (14) (15) (16) . Genetic deletion of inflammasome components or pharmacological inhibition of caspase activity inhibits HMGB1 release (10) (11) (12) (13) (14) (15) . We and others have previously established that vagus nerve stimulation or cholinergic receptor agonists significantly inhibit HMGB1 release and prevent the systemic accumulation of HMGB1 during inflammation (17, 18) . Other findings indicate that the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome mediates HMGB1 release during endotoxemia or bacteremia (10) (11) (12) and that cytosolic oxidized mitochondrial DNA activates the NLRP3 inflammasome (19, 20) . Accordingly, here we postulated that cholinergic agonists inhibit NLRP3 inflammasome activation by preventing mitochondrial DNA release.
MATERIALS AND METHODS

Reagents
Lipopolysaccharides (LPS; Escherichia coli, 0111:B4), acetylcholine and adenosine triphosphate (ATP) were purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA). Anti-mouse IL-1β (sc-1251), antimouse caspase-1 (sc-514) and anti-human caspase-1 (sc-622) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse anti-HMGB1 mAb IgG2b 2G7 (noncommercial antibody) is originally from Critical Therapeutic (Boston, MA, USA), available upon request.
Plasmids expressing procaspase-1, ASC, NLRP3 or α7 nAchR were purchased from Origene (Rockville, MD, USA). Mitotracker green and Mitotracker deep red were purchased from Invitrogen/Life Technologies (Carlsbad, CA, USA). Mitochondrial isolation and purification kits were from Qiagen (Germantown, MD, USA). Choline/acetylcholine assay kits were from Abcam (Cambridge, MA, USA). Murine macrophage colonystimulating factor (GM-CSF) and human macrophage colony-stimulating factor (M-CSF) were purchased from Peprotech (Rocky Hill, NJ, USA).
Mice and Vagus Nerve Stimulation
Mice deficient for the α7 nicotinic receptor (C57BL/6 background) and WT littermates were purchased from The Jackson Laboratory (Bar Harbor, ME, USA; B6.129S7-Chrna 7tm1Bay , number 003232 
Cell Isolation and Culture
Peritoneal mouse macrophages. Peritoneal mouse macrophages were isolated as described previously (15) . Briefly, mice were injected intraperitoneally with 4% of sterile thioglycollate solution 3-5 d before macrophage isolation. Mice were euthanized with CO 2 and were then injected intraperitoneally with 11.6% of sterile sucrose solution. Peritoneal lavage was collected and filtered through a cell strainer with a pore size of 40 μm. Cells were spinned down at 400g for 15 min. The cell pellets were then resuspended in macrophage culture medium (RPMI medium 1640 supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin).
Bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells (BMDCs) were generated in vitro from bone marrow cells from 6-to 8-wk-old mice as previously described (15) . Briefly, femurs and tibias were flushed with RPMI-1640 to release the bone marrow cells in RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum, 100 mg/mL penicillin, 100 mg/mL streptomycin and 5 × 10 -5 mol/L mercaptoethanol (20 ng/mL murine GM-CSF). On d 3, the supernatants were gently removed and replaced with the same volume of media. On d 6, the nonadherent cells were collected. Human macrophages. Primary blood mononuclear cells were isolated by density-gradient centrifugation. Then cells were collected and cultured in RPMI 1640 medium with 10% heatinactivated human serum. After 2 h incubation at 37°C, adherent cells were detached with 10 mmol/L ethylenediaminetetraacetic acid (EDTA), and then resuspended (10 6 cells/mL) in medium supplemented with human macrophage colony-stimulating factor (20 ng/mL) and cultured for 7 d. Cell stimulation. The 10 6 peritoneal mouse macrophages or M-CSFdifferentiated human macrophages plated in 12-well plates were primed with ultrapure LPS (500 ng/mL) for 4 h and then pulsed with ATP (5 mmol/L) for 30 min.
ELISA
Levels of IL-1β, IL-18 and IL-6 in the culture medium or mouse serum samples were determined using quantitative ELISA kits (R&D Systems, Minneapolis, MN, USA) with reference to standard curves of purified recombinant proteins at various dilutions.
Western Blot Analysis
Proteins from cell-free supernatants were extracted by methanol/chloroform precipitation as described previously (15) . Briefly, cell culture supernatants were precipitated by the addition of an equal volume of methanol and 0.25 volumes of chloroform and then were vortexed and centrifuged for 10 min at 20,000g. The upper phase was discarded and 500 μL methanol was added to the interphase. This mixture was centrifuged for 10 min at 20,000g, and the protein pellet was dried at 55°C, resuspended in Laemmli buffer and boiled for 5 min at 99°C. Cell extracts were prepared as described previously. Samples were separated by 4-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE) or 4-20% native PAGE and were transferred onto polyvinylidene fluoride membranes.
Reconstituted Inflammasome in HEK293A Cells
For the human NLRP3 inflammasome reconstitution assays, 0.2 × 10 6 HEK293A cells were seeded onto 24-well plates in cell culture media lacking antibiotics. Then, 24 h later, cells were transfected with plasmids expressing pro-IL-1β and inflammasome components (Origene), such as ASC, procaspase-1 and NLRP3 by using lipofectamine 2000. These modified cells were then cotransfected with either plasmids that express α7 nAchR or empty plasmids (Origene). The total amount of DNA was standardized to 600 ng per well by using a control plasmid. The transfection efficiency was monitored by using a GFP-encoding plasmid and fluorescent microscopy, and the transfection rate was observed to be around 70%. Cell lysates were harvested 24 h later and analyzed for caspase-1 cleavage by Western blot analysis. Nontransfected HEK293A cells do not express detectable procaspase-1. Caspase-1 activation was standardized by levels of procaspase-1 in cell lysates of transfected HEK293A cells.
Acetylcholine Assay
Mouse peritoneal macrophages were primed with LPS for 3 h. And cells were stimulated with ATP (2.5 mmol/L) in the presence or absence of extracellular acetylcholine (1 mmol/L) for the indicated time. Then cells were washed two times with precooled 1× phosphatebuffered saline (PBS) to get rid of extracellular acetylcholine. Cell lysates were obtained, and total choline and acetylcholine levels were assessed by using a choline/ acetylcholine assay kit (Abcam).
Flow Cytometry Analysis
Mitochondrial perturbation was assessed by flow cytometry as described previously (23, 24) with some modifications. Briefly, BMDCs were primed with LPS (200 ng/mL) in 15-mL tubes for 2 h and then stained with Mitotracker green and Mitotracker deep red at 100 nmol/L for 30 min at 37°C. The nonadherent cells were collected and stimulated by ATP (1 mmol/L) for 15 min. Cells were quickly transferred on ice for fluorescence-activated cell sorter analysis.
Mitochondrial DNA Release Assay
The mtDNA levels in cytosol were measured as described previously (20) . Briefly, 1 × 10 7 peritoneal macrophages were homogenized with a dounce homogenizer in the presence of protease inhibitor and then were subjected to centrifugation at 700g for 10 min at 4°C. Protein concentration and volume of the supernatant were normalized, followed by centrifugation at 10,000g for 30 min at 4°C for the production of a supernatant corresponding to the cytosolic fraction. DNA was isolated from 200 μL of the cytosolic fraction by using a DNeasy Blood & Tissue kit (Qiagen).
In the cell-free system, purified mitochondria were stimulated with CaCl 2 or H 2 O 2 (0.5 mmol/L) as described previously (23) . Briefly, the purified mitochondria (120 mg protein per mL) were incubated with either 200 μmol/L CaCl 2 or 0.5 mmol/L H 2 O 2 in the presence or absence of different doses of acetylcholine for 15 min at room temperature and were immediately pelleted by centrifugation (10 min, 7,000g) at 4°C. DNA was isolated from 200 μL mitochondrial supernatant by using a DNeasy Blood & Tissue kit.
The levels of mtDNA encoding cytochrome c oxidase 1 were measured by quantitative real-time PCR with the same volume of the DNA solution. The following primers were used: mouse cy chrome c oxidase I forward, 5′-GCCCCAGATA TAGCATTCCC-3′, and reverse, 5′-GTTCA TCCTGTTCCTGCTCC-3′.
Statistical Analysis
Data are expressed as mean ± standard deviation (SD) of at least three independent experiments (n = 3-5). One-way analysis of variance and Student t test were used for comparison among all different groups. A p value <0.05 was considered statistically significant.
All supplementary materials are available online at www.molmed.org.
RESULTS
Cholinergic Agonists Inhibit Inflammasome Activation
To test the hypothesis that cholinergic neural signals inhibit NLRP3 inflammasome activation, LPS-primed mouse peritoneal macrophages were stimulated with ATP in the presence or the absence of different concentrations of acetylcholine. Acetylcholine exposure dosedependently inhibited ATP-induced activation of caspase-1, cleavage of pro-IL-1β and HMGB1 release ( Figure 1A ). Addition of acetylcholine failed to inhibit the expression of pro-IL-1β in the cell lysates ( Figure 1A ), indicating that inhibition of IL-1β production by acetylcholine is due to the suppression of inflammasome activity, rather than LPS-induced priming. Next, inflammasome activation was as-sessed in human macrophages exposed to acetylcholine. Human macrophages did not secrete detectable amounts of IL-1β after LPS stimulation ( Figure 1B) . However, ATP subsequent stimulation of LPS-primed human macrophages rapidly induced IL-1β secretion, which was dosedependently inhibited by acetylcholine. In contrast, addition of acetylcholine failed to attenuate LPS-induced IL-6 production, which does not depend on inflammasome activation ( Figure 1B) . To investigate whether cholinergic neural signals inhibit inflammasome activation in vivo, mice were subjected to vagus nerve stimulation or sham operation. Three hours later, the animals were challenged with lethal doses of LPS. We observed that vagus nerve stimulation significantly reduced serum levels of IL-1β and IL-18, as compared with that of sham operation ( Figure 1C ); IL-6 was not inhibited by vagus nerve stimulation ( Figure  1C ). Finally, inflammasome activity was assessed in LPS-primed mouse peritoneal macrophage-activated ATP in the presence or absence of GTS-21, an α7 nAchR agonist. GTS-21 dose-dependently inhibited ATP-induced IL-1β cleavage ( Figure  1D ). Together, these observations indicate that cholinergic agonists inhibit inflammasome activation in vitro and in vivo.
α7 nAchR Signaling Inhibits the NLRP3 Inflammasome Activation
The major target of GTS-21 is α7 nAchR, which is expressed in macrophages and dendritic cells (21) . Together with our previous findings that α7 nAchR is an important regulator of inflammation and an essential component of the inflammatory reflex (22), we reasoned that cholinergic agonists might inhibit the NLRP3 inflammasome activation through interaction with α7 nAchR. To test this hypothesis, we challenged both α7 nAchR knockout (α7 KO) mice and wild-type (WT) controls with a lethal dose of LPS. Notably, the serum levels of IL-1β and IL-18 were significantly higher in α7 KO compared with that of WT mice (Figure 2A ). The production of IL-6, however, was not significantly altered in α7 KO mice (Figure 2A ). Genetic deletion of α7 nAchR also significantly increased IL-1β cleavage in peritoneal mouse macrophages in vitro ( Figure 2B ). These results indicate that α7 nAchR negatively regulates inflammasome activation.
To further investigate the role of α7 nAchR in NLRP3 inflammasome activation, we reconstituted the functional NLRP3 inflammasome in nonimmune HEK293A cells by transfection of these cells with plasmids that encode inflammasome components NLRP3, ASC and procaspase-1 (15) . Western blot analysis reveals that expression of these inflammasome components in HEK293A cells induces cleavage of procaspase-1; this is indicative of a functional inflammasome ( Figure 2C ). Coexpression of α7 nAchR in these genetically modified cells significantly inhibited the cleavage of procaspase-1. Addition of a selective α7 nAchR agonist (PNU-28879) further decreased activation of caspase-1 (Figure 2C) . Collectively, these findings establish that α7 nAchR signaling inhibits NLRP3 inflammasome activation.
α7 nAchR Signaling Attenuates ATPInduced Mitochondrial Perturbation
Prior work implicated mitochondrial perturbation in NLRP3 inflammasome activation (23) . ATP stimulation mobilizes Ca 2+ from the endoplasmic reticulum or extracellular space to the cytoplasm, and the resultant increase in mitochondrial permeability has been linked to the NLRP3 inflammasome activation (24) . α7 nAchR is expressed in the mitochondrial outer membrane in nonneuronal cells, including monocytes, B lymphocytes and hepatocytes (25, 26) . To confirm that α7 nAchR is localized in mitochondria, we transfected HEK293 cells with Myctagged α7 nAchR and then stained the genetically modified cells with the antiMyc antibodies and a mitochondrial marker. Indeed, we observed the localization of Myc-tagged α7 nAchR in mitochondria (Supplementary Figure S1) . We next hypothesized that α7 nAchR signaling attenuates ATP-induced mitochondrial perturbation. To test this, we incubated primary BMDCs with MitoTrack green and MitoTrack deep red to stain total mitochondria and mitochondria with normal membrane potential, respectively. Consistent with previous studies, LPS and ATP stimulation resulted in robust increase of cells that had lost mitoTrack deep red staining, indicative of mitochondrial perturbation in these cells (Figure 3 ). Genetic deletion of α7 nAchR significantly enhanced ATP-induced mitochondrial perturbation in LPS-prime BMDCs ( Figure 3A) . Further, acetylcholine dose-dependently inhibited ATP-induced mitochondrial perturbation in WT, but not in α7 nAchR knockout (a7 KO), BMDCs ( Figures 3B-E) , indicating that α7 nAchR signaling attenuates ATP-induced mitochondrial perturbation.
Acetylcholine Accumulates in Cytoplasm upon ATP Stimulation
Although it is known that acetylcholine and other α7 nAchR agonists abolish Ca 2+ or hydrogen oxide-induced cytochrome c release from isolated mitochondria (25) , the mechanism for extracellular acetylcholine translocation into cytoplasm has remained unknown. One possibility is that extracellular acetylcholine accumulates in the cytoplasm of immune cells upon ATP stimulation. To test this, LPSprimed mouse peritoneal macrophages were stimulated with ATP in the presence of extracellular acetylcholine (1 mmol/L), and acetylcholine levels in cell lysates were subsequently measured. We observed that ATP stimulation induced increased acetylcholine levels in the cell lysates ( Figure 4A ), indicating that extracellular acetylcholine accumulates in cytoplasm on ATP stimulation. This process does not depend on α7 nAchR, because genetic deletion of α7 nAchR did not block ATP-induced acetylcholine accumulation in the cell lysates ( Figure 4B ). Previous studies show that ATP stimulation could result in the formation of pannexin pores that increase permeability of cytoplasmic membrane to small molecules (<900 Da) (27) . To determine whether pannexin is involved in ATPinduced acetylcholine accumulation in cell lysates, mouse macrophages were stimulated with ATP in the presence of Panx-10, a peptide that is reported to block the pannexin pores (27) , or a control peptide. Notably, addition of Panx-10 did not significantly inhibit ATP-induced acetylcholine accumulation in cell lysates, as compared with that of control peptide ( Figure 4C) . Collectively, these results demonstrated that acetylcholine rapidly accumulates in the cytoplasm of immune cells on ATP stimulation in an α7 nAchRand pannexin-independent manner.
α7 nAchR Signaling Prevents Mitochondrial DNA Release
Early studies indicate that mitochondrial DNA release into cytoplasm is associated with NLRP3 inflammasome activation (19, 20) . Oxidized mitochondrial DNA molecules function as NLRP3 ligands that induce the assembly and activation of the NLRP3 inflammasome (19) . Accordingly, we reasoned that α7 nAchR signaling prevents mitochondrial DNA release into cytoplasm. Mouse macrophages were stimulated with ATP in the presence of different concentrations of acetylcholine. Then the cytoplasmic fraction was extracted, and mitochondrial DNA levels were assessed by using quantitative polymerase chain reaction (qPCR) with primers for the cytochrome c oxidase 1 gene. Indeed, acetylcholine dose-dependently inhibited ATP-induced mitochondrial DNA release into cytoplasm in WT macrophages ( Figure 5A ). However, acetylcholine did not significantly inhibit ATP-induced mitochondrial DNA release into cytoplasm in α7 nAchR knockout (α7 KO) macro phages, even at the higher concentration ( Figure 5B ). These data indicate that acetylcholine inhibits ATP-induced mitochondrial DNA release into cytoplasm in an α7 nAchR-dependent manner. Further, we asked whether acetylcholine could inhibit mitochondrial DNA release in isolated mitochondria in a cell-free system. Macro phage mitochondria were isolated and then challenged with Ca 2+ or hydrogen oxide in the presence of different doses of acetylcholine. Mitochondrial DNA levels in supernatant were measured by qPCR. Addition of acetylcholine significantly inhibited Ca 2+ or hydrogen oxide-induced mitochondrial DNA release (Figures 5C, D) . Mitophagy is a selective form of autophagy by which injured mitochondria are degraded into auto-lysosomes. Recent studies have shown that activation of autophagy/mitophagy by inflammatory signals limits IL-1β production (20) .
To study the role of α7 nAchR signaling in regulation of autophagy, LPS-primed mouse macro phages were stimulated with ATP in the presence of different concentration of acetylcholine for 20 min. Exposure to acetylcholine did not alter the cellular levels of LC3B-II (Supplementary Figure S2) , suggesting that α7 nAchR signaling prevents mitochondrial DNA release in an autophagyindependent manner.
DISCUSSION
These findings establish an important mechanism of mitochondrial α7 nAchR signaling in regulation of the NLRP3 inflammasome activation that reduces mitochondrial DNA release. Inflammasomes are intracellular protein complexes that mediate maturation of IL-1β and IL-18 and execute the process of proinflammatory programmed cell death (termed "pyroptosis"). Unlike other types of inflammasomes, the NLRP3 inflammasome can be triggered by a broad range of endogenous and exogenous danger signals (28) . Instead of binding NLRP3 directly, these stimuli activate the NLRP3 inflammasome by provoking intracellular potassium efflux and mitochondrial DNA release into cytoplasm (19, 29) . In this study, we found that stimulation of ATP results in a rapid influx of acetylcholine into the cytoplasm, enabling intracellular acetylcholine to interact with mitochondrial α7 nAchR and in turn prevent mitochondrial DNA release ( Figure 6 ). Because oxidized mitochondrial DNA molecules bind and activate the NLRP3 inflammasome (19) , our findings provide a mechanism for acetylcholine inhibition of ATPinduced NLRP3 inflammasome activation by preventing mitochondrial DNA release into cytoplasm. It is noteworthy that other NLRP3 inflammasome agonists, such as nigericin and adjuvant aluminum, have also been implicated in inducing the influx of acetylcholine into the cytoplasm through formation of pores in the cytoplasmic membrane and after lysosomal damage, respectively.
The inflammasome-dependent cytokines IL-1β, IL-18 and HMGB1 orchestrate the inflammatory responses to infection and sterile tissue injury. However, deregulated production of these cytokines drives the pathogenesis of many inheritable or acquired diseases and disorders, such as obesity, type 2 diabetes, atherosclerosis, arthritis, colitis and sepsis (30) . Interestingly, cholinergic neural signals also inhibit the production of inflammasome-independent cytokines, including tumor necrosis factor (31) . This study reveals a novel pathway through which cholinergic agonists may modulate target cells by activating intracellular cholinergic receptors on mitochrondria. Although emerging evidence shows that many nonneuron cells (such as monocytes, B lymphocytes and hepatocytes) contain intracellular pools of nicotinic cholinergic receptors, the biological function of these intracellular cholinergic receptors had previously been elusive (25, 26) . Figure 6 . The mechanisms by which acetylcholine inhibits inflammasome activation. Extracellular ATP activates the NLRP3 inflammasome by provoking intracellular potassium efflux and mitochondrial DNA release into cytoplasm. Stimulation of ATP also results in rapid influx of acetylcholine into cytoplasm. There, acetylcholine prevents mitochondrial DNA release through α7 nAchR and subsequently inhibits the NLRP3 inflammasome activation.
